Announcement PDF ASX Release Attaching Options, exercisable at 5.25 cents, expiring 19 February 2027 - final due date for applications 31 March 2025 Melbourne, Australia; 7 March 2025 In December 2024 Acrux Limited (ASX:ACR, “Acrux” or the “Company”) raised $4 million before costs through a Share Purchase Plan (‘SPP’) and a Share Placement. Each share issued carried a right for the subscriber to apply for one free Attaching Option (‘Option’). The Offer of Options was made under the terms and conditions detailed in the Options Prospectus and the Offer documents which were issued to subscribers on 17 January 2025. The Appendix 2A to issue these Options was announced on 19 February 2025. The Options are listed under the ASX code ACRO and as specified in the Options Prospectus have an exercise price of 5.25 cents and an expiry date of 19 February 2027. The exercise price was incorrectly noted on page 4 of the Appendix 2A – the correct exercise price is 5.25 cents. Options have not been allocated to SPP subscribers who did not accept the Offer by the due date. For these SPP subscribers the acceptance period has been extended to 31 March 2025 and there will be no further extension past this date. Please direct any questions in relation to acceptances or the allocation of Attaching Options to info@acrux.com.au. Approved for release by the Board of Acrux Limited. For more information, please contact: Michael Kotsanis Acrux Limited CEO & Managing Director P: + 61 3 8379 0100 E: michael.kotsanis@acrux.com.au About Acrux Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit www.acrux.com.au